Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia-positive clone or variant Philadelphia translocations

Simone Claudiani; Lynette Chee; Fiona Fernando; Loretta Brown; Udayakumar M Achandira; Afzal Khan; Kate Rothwell; Chloe Hayden; Ioannis Koutsavlis; Guy Hannah; Andrew Innes; Jane F Apperley; Dragana Milojkovic

doi:10.1002/ajh.27278

Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia-positive clone or variant Philadelphia translocations

Am J Hematol. 2024 Mar 4. doi: 10.1002/ajh.27278. Online ahead of print.

Authors

Simone Claudiani^{1

2}, Lynette Chee³, Fiona Fernando^{1

2}, Loretta Brown⁴, Udayakumar M Achandira⁴, Afzal Khan^{1

2}, Kate Rothwell⁵, Chloe Hayden⁶, Ioannis Koutsavlis⁷, Guy Hannah⁸, Andrew Innes^{1

2}, Jane F Apperley^{1

2}, Dragana Milojkovic^{1

2}

Affiliations

¹ Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
² Centre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK.
³ Department of Clinical Haematology, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, Victoria, Australia.
⁴ Department of Molecular Pathology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
⁵ Department of Clinical Haematology, Leeds Teaching Hospital NHS Trust, Leeds, UK.
⁶ Imperial Molecular Pathology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
⁷ Hematology Department, Western General Hospital, Edinburgh, UK.
⁸ King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, London, UK.

PMID: 38436141
DOI: 10.1002/ajh.27278

Abstract

Probability of treatment-free remission (TFR) in CML patients with additional chromosomal abnormalities (ACA) in the Philadelphia-positive clone or variant Philadelphia translocations (ACA/Var-Ph group, blue panel), in those with no cytogenetic abnormality other than the classical Philadelphia translocation (c-Ph group, green panel) and in the subgroups of CML patients with high-risk ACA (HR-ACA, yellow panel) and Var-Ph (red panel).

Publication types

Letter